← Azimuth Daily
Capturing data…
Capturing data…
THU, 12 NOV · 87 ITEMS
"Next-generation KRAS G12C inhibitor improves survival in lung cancer" — Nature Medicine · Science & Medicine
This is a report on a Phase 3 clinical trial showing that , a next-generation , improves survival outcomes in patients with KRAS G12C-mutant non-small cell lung cancer. The study, published in Nature Medicine, compared divarasib to first-generation inhibitors sotorasib and adagrasib and found longer and a reduced risk of disease progression.
The claim is based directly on a peer-reviewed study in Nature Medicine, a primary source. The reporting is close to the source and the headline accurately reflects the trial's findings.
The study was published in Nature Medicine in November 2026, making this genuinely new research.
We covered the initial results of this trial in October 2026, when Roche announced that divarasib outperformed first-generation KRAS G12C inhibitors in a Phase 3 trial.